Corporate Liaison Board Mission Statement

The Corporate Liaison Board of The Endocrine Society serves as a forum for communication between The Endocrine Society, The Hormone Foundation and the pharmaceutical and biotechnology industry in endocrinology. As such, the Board:

• Promotes reciprocal access to the business, medical and scientific leadership of the respective organizations;
• Integrates industry trends and needs with strategic objectives of the Society and The Hormone Foundation;
• Fosters partnerships and collaborations between the Society, The Hormone Foundation and industry involving projects and services of common interest;
• Recognizes the scientific and professional contributions of Society members who work in industry.

Approved by CLB Planning Group on November 20, 1998 Approved by The Endocrine Society Council on January 9, 1999 Approved Revision by The Endocrine Society Council on June, 2004

Learn more information about the goals of the Corporate Liaison Board.

CORPORATE LIAISON BOARD MEMBERS

Abbott Laboratories
Allergan
Amgen
AstraZeneca
Boehringer Ingelheim Pharmaceuticals, Inc.
Bristol-Myers Squibb
Genentech, Inc.
Genzyme Corporation
GlaxoSmithKline, Inc.
Ipsen, US
Johnson & Johnson
Lilly Diabetes
Medtronic Diabetes
Merck & Co., Inc.
Novartis Pharmaceuticals Corporation
Novo Nordisk Inc.
Pfizer, Inc.
Sanofi-Aventis
Takeda Pharmaceuticals North America, Inc